Author

F. Sacco

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Approach:machine learning (classical)· 1 Assay:proteomics· 1

Frequent Co-Authors

D. Mougiakakos· 2 shared G. M. Pugliese· 2 shared G. Massacci· 2 shared L. Perfetto· 2 shared M. Boettcher· 2 shared S. Latini· 2 shared T. Fischer· 2 shared V. Bica· 2 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Mougiakakos

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivJun 22, 2023

Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction

S. Latini, V. Venafra, G. Massacci…·F. Sacco

This study develops a systems-based strategy to predict drug sensitivity in FLT3-ITD AML by integrating genomic, transcriptomic data with a prior-knowledge signaling network.

DOI 10.7554/elife.90532.3

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivMay 16, 2022

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients

G. Massacci, V. Venafra, S. Latini…·F. Sacco

The paper identifies the WEE1-CDK1 axis as a key driver of TKI resistance in FLT3-ITD positive AML and suggests combination therapy as a potential treatment.

DOI 10.1038/s41375-022-01785-w

humanproteomics

𝕏 PostBluesky